Live price temporarily unavailable.
Roivant Sciences (ROIV) is a Health Care company in the Russell 1000. Latest news and coverage below.
| FY2020Mar 2021 | FY2021Mar 2022 | FY2022Mar 2023 | FY2023Mar 2024 | FY2024Mar 2025 | FY2025Mar 2026 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | $23.8M | $55.3M | $31.5M | $32.7M | $29.1M | $8.26M |
| Growth (year over year) | — | +132.3% | −43.0% | +3.8% | −11.2% | −71.6% |
| Operating income | −$1.07B | −$1.35B | −$906.8M | $4.50B | −$1.00B | −$515.1M |
| Operating margin | −4500.5% | −2444.8% | −2875.9% | 13746.9% | −3453.3% | −6235.7% |
| Net income | −$809.2M | −$845.3M | −$1.01B | $4.35B | −$172.0M | −$299.8M |
| Net margin | −3400.9% | −1528.9% | −3200.2% | 13294.2% | −592.0% | −3629.2% |
| EPS (diluted) | −$1.28 | −$1.26 | −$1.42 | $5.23 | −$0.24 | −$0.54 |
| Balance sheet | ||||||
| Cash and equivalents | $2.06B | $2.06B | $1.68B | $6.49B | $2.72B | $1.42B |
| Total assets | $2.59B | $2.59B | $2.39B | $7.22B | $5.44B | $5.71B |
| Total liabilities | $527.7M | $523.7M | $782.0M | $774.0M | $249.7M | $416.3M |
| Long-term debt | $170.3M | $210.0M | $375.5M | $430.6M | — | — |
| Shareholders' equity | $1.80B | $1.66B | $1.16B | $5.97B | $4.69B | $4.53B |
| Cash flow | ||||||
| Operating cash flow | −$552.1M | −$677.7M | −$843.4M | −$765.3M | −$839.5M | −$750.3M |
| Capital expenditure | $5.81M | $17.4M | $12.7M | $1.38M | $4.60M | $8.21M |
| Free cash flow | −$557.9M | −$695.2M | −$856.1M | −$766.6M | −$844.0M | −$758.6M |
| Share buybacks | — | — | $0 | $0 | $1.29B | — |
| Q2 FY24Sep 2024 | Q3 FY24Dec 2024 | Q4 FY24†Mar 2025 | Q1 FY25Jun 2025 | Q2 FY25Sep 2025 | Q3 FY25Dec 2025 | Q4 FY25†Mar 2026 | Q1 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $4.47M | $9.02M | $7.57M | $2.17M | $1.57M | $2.00M | $2.52M | $1.44M |
| Growth (year over year) | +22.7% | −42.1% | — | −72.8% | −64.9% | −77.8% | −66.7% | −33.5% |
| Operating income | −$341.7M | −$274.4M | −$285.0M | −$284.9M | −$306.2M | −$339.2M | $415.2M | −$366.0M |
| Operating margin | −7636.0% | −3042.6% | −3764.4% | −13130.0% | −19492.9% | −16966.1% | 16477.8% | −25380.9% |
| Net income | −$230.2M | $169.4M | −$206.5M | −$223.4M | −$113.5M | −$265.9M | $303.0M | −$189.8M |
| Net margin | −5143.8% | 1878.3% | −2727.5% | −10292.9% | −7225.9% | −13301.2% | 12023.6% | −13164.8% |
| EPS (diluted) | −$0.31 | $0.23 | −$0.28 | −$0.33 | −$0.17 | −$0.38 | $0.34 | −$0.26 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.96B | $1.99B | $2.72B | $1.24B | $1.24B | $1.48B | $1.42B | $1.25B |
| Total assets | $6.21B | $5.79B | $5.44B | $5.03B | $5.06B | $5.23B | $5.71B | $5.31B |
| Total liabilities | $626.0M | $256.4M | $249.7M | $216.7M | $257.1M | $251.1M | $416.3M | $384.6M |
| Shareholders' equity | $5.15B | $5.19B | $4.69B | $4.35B | $4.36B | $4.27B | $4.53B | $4.23B |
| Cash flow | ||||||||
| Operating cash flow | −$266.8M | −$207.3M | −$172.6M | −$204.4M | −$185.7M | −$196.5M | −$163.8M | −$270.5M |
| Capital expenditure | $996.0K | $1.83M | $811.0K | $4.04M | $7.85M | −$4.93M | $1.26M | $419.0K |
| Free cash flow | −$267.8M | −$209.1M | −$173.4M | −$208.4M | −$193.5M | −$191.5M | −$165.1M | −$270.9M |
| Share buybacks | $106.1M | $243.3M | $295.4M | $208.3M | $0 | $0 | — | $206.7M |
From Roivant Sciences's 10-K and 10-Q filings with the SEC; its fiscal year ends in March. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.
Source: Wikipedia — Roivant Sciences
No recent news mentioning Roivant Sciences in our feed yet.